149 related articles for article (PubMed ID: 1126567)
21. Neuraminidase- and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B-Eng-13-65 virus vaccines.
Downie JC
J Immunol; 1970 Sep; 105(3):620-6. PubMed ID: 5311581
[No Abstract] [Full Text] [Related]
22. Standardization of assays of neuraminidase and its antibody.
Bevan AM; Stones PB
Dev Biol Stand; 1977 Jun 1-3; 39():485-8. PubMed ID: 75119
[TBL] [Abstract][Full Text] [Related]
23. [On the antigenicity of influenza virus aluminum oxide adjuvant vaccine "Alorbat" in man (author's transl)].
Desselberger U; Pressler K; Erdmann G
Zentralbl Bakteriol Orig A; 1975 Jul; 232(2-3):160-77. PubMed ID: 1179878
[TBL] [Abstract][Full Text] [Related]
24. A comparison of "influenza C" with prototype myxoviruses: receptor-destroycing activity (neuraminidase) and structural polypeptides.
Kendal AP
Virology; 1975 May; 65(1):87-99. PubMed ID: 49979
[No Abstract] [Full Text] [Related]
25. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
[TBL] [Abstract][Full Text] [Related]
26. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
[TBL] [Abstract][Full Text] [Related]
27. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
[TBL] [Abstract][Full Text] [Related]
28. Attenuated ts-recombinants of influenza A/USSR/77 (H1N1) virus obtained by crossing with the cold-adapted donor A/Leningrad/134/57 (H2N2) virus.
Polezhaev FI; Garmashova LM; Koval TA; Taranova GP; Topuriya NV; Aleksandrova GI
Acta Virol; 1982 Jul; 26(4):221-6. PubMed ID: 6127928
[TBL] [Abstract][Full Text] [Related]
29. Neuraminidase antibodies and H5N1: geographic-dependent influenza epidemiology could determine cross-protection against emerging strains.
Bermejo-Martin JF; Kelvin DJ; Guan Y; Chen H; Perez-Breña P; Casas I; Arranz E; de Lejarazu RO
PLoS Med; 2007 Jun; 4(6):e212. PubMed ID: 17593897
[No Abstract] [Full Text] [Related]
30. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.
Chen J; Fang F; Li X; Chang H; Chen Z
Vaccine; 2005 Jul; 23(34):4322-8. PubMed ID: 15925433
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Jadhao SJ; Lee CW; Sylte M; Suarez DL
Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
[TBL] [Abstract][Full Text] [Related]
32. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
[TBL] [Abstract][Full Text] [Related]
33. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection.
Sylte MJ; Hubby B; Suarez DL
Vaccine; 2007 May; 25(19):3763-72. PubMed ID: 17350145
[TBL] [Abstract][Full Text] [Related]
34. Antineuraminidase antibody response of man to influenza virus neuraminidase N2: results obtained with an improved hemagglutination inhibition technique and an enzyme inhibition test.
Hennessy AV; Minuse E; Davenport FM
J Immunol; 1972 Aug; 109(2):213-6. PubMed ID: 5047368
[No Abstract] [Full Text] [Related]
35. The neuraminidase of influenza virus.
Air GM; Laver WG
Proteins; 1989; 6(4):341-56. PubMed ID: 2482974
[TBL] [Abstract][Full Text] [Related]
36. Neuraminidase assays.
Aymard M; Ferraris O; Gerentes L; Jolly J; Kessler N
Dev Biol (Basel); 2003; 115():75-83. PubMed ID: 15088778
[TBL] [Abstract][Full Text] [Related]
37. Neuraminidase-inhibition assay for the identification of influenza A virus neuraminidase subtype or neuraminidase antibody specificity.
Pedersen JC
Methods Mol Biol; 2008; 436():67-75. PubMed ID: 18370042
[TBL] [Abstract][Full Text] [Related]
38. Development of antibodies to neuraminidase of A2-Hong Kong and A2-Taiwan influenza viruses after administration of different Hong Kong vaccines and after natural infection in humans.
Závadová H
Acta Virol; 1973 Jul; 17(4):287-92. PubMed ID: 4148207
[No Abstract] [Full Text] [Related]
39. Studies on the role of myxovirus neuraminidase in virus-cell receptors interaction by means of direct determination of sialic acid split from cells. I. Experiments on influenza virus-RBC cell system.
Tsvetkova IV; Lipkind MA
Arch Gesamte Virusforsch; 1968; 23(4):299-312. PubMed ID: 4971430
[No Abstract] [Full Text] [Related]
40. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
